203 related articles for article (PubMed ID: 38175716)
1. 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer.
Li K; Liu W; Yu H; Chen J; Tang W; Wang J; Qi M; Sun Y; Xu X; Zhang J; Li X; Guo W; Li X; Song S; Tang S
J Clin Invest; 2024 Jan; 134(4):. PubMed ID: 38175716
[TBL] [Abstract][Full Text] [Related]
2. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
3. First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer.
Wegen S; Roth KS; Weindler J; Claus K; Linde P; Trommer M; Akuamoa-Boateng D; van Heek L; Baues C; Schömig-Markiefka B; Schomäcker K; Fischer T; Drzezga A; Kobe C; Köhler C; Marnitz S
Clin Nucl Med; 2023 Feb; 48(2):150-155. PubMed ID: 36607364
[TBL] [Abstract][Full Text] [Related]
4. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu Q; Deng M; Hu M; Liu M; Chen X; Chen Y; Cai L
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1442-1452. PubMed ID: 36609606
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer.
Li K; Liu W; Yu H; Chen J; Tang W; Wang J; Qi M; Sun Y; Xu X; Zhang J; Li X; Guo W; Li X; Song S; Tang S
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618961
[No Abstract] [Full Text] [Related]
6. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.
Tatar G; Beyhan E; Erol Fenercioğlu Ö; Arslan E; Çermik TF
Clin Nucl Med; 2022 Sep; 47(9):e596-e599. PubMed ID: 35930714
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of [
Zhao L; Pang Y; Zheng H; Han C; Gu J; Sun L; Wu H; Wu S; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3606-3617. PubMed ID: 33792760
[TBL] [Abstract][Full Text] [Related]
8. The potential role of 68Ga-FAPI-04 PET/CT for screening malignancy in suspected colonic lesions.
Erol Fenercioğlu Ö; Beyhan E; Şahin R; Baloğlu MC; Arslan E; Çermik TF; Ergül N
Nucl Med Commun; 2023 Oct; 44(10):896-899. PubMed ID: 37450605
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Activation Protein-Targeted PET/CT with
Xu W; Cai J; Peng T; Meng T; Pang Y; Sun L; Wu H; Zhang J; Chen X; Chen H
J Nucl Med; 2024 Jan; 65(1):40-51. PubMed ID: 37884330
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract][Full Text] [Related]
11. PET/CT imaging fibroblast activation protein in initial colorectal cancer: compared to 18 F-FDG PET/CT.
Dong Y; Sun P; Wu H; Zhong J; Cao M; Tang G; Zhou W
Nucl Med Commun; 2023 Nov; 44(11):1011-1019. PubMed ID: 37661771
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of Ga-68 FAPI 04 PET/CT in colorectal malignancies.
Prashanth A; Kumar Ravichander S; Eswaran P; Kalyan S; Maheswari Babu S
Nucl Med Commun; 2023 Apr; 44(4):276-283. PubMed ID: 36756771
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer.
Fu H; Fu J; Huang J; Pang Y; Chen H
Clin Nucl Med; 2021 Nov; 46(11):940-942. PubMed ID: 34034326
[TBL] [Abstract][Full Text] [Related]
14. [
Zheng J; Liu F; Lin K; Zhang L; Huang N; Zheng W; Zhang J; Yao S; Miao W
Mol Imaging Biol; 2022 Dec; 24(6):973-985. PubMed ID: 35945360
[TBL] [Abstract][Full Text] [Related]
15. Dual-tracer PET/CT protocol with [
Wegen S; Weindler J; Voltin CA; van Heek L; Schomäcker K; Fischer T; Marnitz S; Kobe C; Drzezga A; Roth KS
Strahlenther Onkol; 2024 Jan; 200(1):28-38. PubMed ID: 37584717
[TBL] [Abstract][Full Text] [Related]
16. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [
Guo W; Pang Y; Yao L; Zhao L; Fan C; Ke J; Guo P; Hao B; Fu H; Xie C; Lin Q; Wu H; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1604-1617. PubMed ID: 33179149
[TBL] [Abstract][Full Text] [Related]
17. Comparing the clinical value of baseline [
Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Li X; Huo L
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4036-4050. PubMed ID: 37493664
[TBL] [Abstract][Full Text] [Related]
18. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using
Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
[TBL] [Abstract][Full Text] [Related]
19. Comparison of
Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
[TBL] [Abstract][Full Text] [Related]
20. Superior Tumor Detection for
Pabst KM; Trajkovic-Arsic M; Cheung PFY; Ballke S; Steiger K; Bartel T; Schaarschmidt BM; Milosevic A; Seifert R; Nader M; Kessler L; Siveke JT; Lueckerath K; Kasper S; Herrmann K; Hirmas N; Schmidt HH; Hamacher R; Fendler WP
J Nucl Med; 2023 Jul; 64(7):1049-1055. PubMed ID: 37024301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
